CREATE: Cross-tumoral Phase 2 With Crizotinib

NCT01524926 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
582
Enrollment
NETWORK
Sponsor class

Conditions

Interventions

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators